Cargando…
Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease
The aetiology of inflammatory bowel diseases (IBD) seems to be strongly connected to changes in the enteral microbiome. The dysbiosis pattern seen in Crohn’s disease (CD) differs among published studies depending on patients’ age, disease phenotype and microbiome research methods. The aims was to in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906406/ https://www.ncbi.nlm.nih.gov/pubmed/31827191 http://dx.doi.org/10.1038/s41598-019-55290-9 |
_version_ | 1783478338699919360 |
---|---|
author | Kowalska-Duplaga, Kinga Gosiewski, Tomasz Kapusta, Przemysław Sroka-Oleksiak, Agnieszka Wędrychowicz, Andrzej Pieczarkowski, Stanisław Ludwig-Słomczyńska, Agnieszka H. Wołkow, Paweł P. Fyderek, Krzysztof |
author_facet | Kowalska-Duplaga, Kinga Gosiewski, Tomasz Kapusta, Przemysław Sroka-Oleksiak, Agnieszka Wędrychowicz, Andrzej Pieczarkowski, Stanisław Ludwig-Słomczyńska, Agnieszka H. Wołkow, Paweł P. Fyderek, Krzysztof |
author_sort | Kowalska-Duplaga, Kinga |
collection | PubMed |
description | The aetiology of inflammatory bowel diseases (IBD) seems to be strongly connected to changes in the enteral microbiome. The dysbiosis pattern seen in Crohn’s disease (CD) differs among published studies depending on patients’ age, disease phenotype and microbiome research methods. The aims was to investigate microbiome in treatment-naive paediatric patients to get an insight into its structure at the early stage of the disease in comparison to healthy. Stool samples were obtained from controls and newly diagnosed patients prior to any intervention. Microbiota was analysed by 16SrRNAnext-generation-sequencing (NGS). Differences in the within-sample phylotype richness and evenness (alpha diversity) were detected between controls and patients. Statistically significant dissimilarities between samples were present for all used metrics. We also found a significant increase in the abundance of OTUs of the Enterococcus genus and reduction in, among others, Bifidobacterium (B. adolescentis), Roseburia (R.faecis), Faecalibacterium (F. prausnitzii), Gemmiger (G. formicilis), Ruminococcus (R. bromii) and Veillonellaceae (Dialister). Moreover, differences in alpha and beta diversities in respect to calprotectin and PCDAI were observed: patients with calprotectin <100 µg/g and with PCDAI below 10 points vs those with calprotectin >100 µg/g and mild (10–27.7 points), moderate (27.5–40 points) or severe (>40 points) CD disease activity had higher richness and diversity of gut microbiota. The results of our study highlight reduced diversity and dysbiosis at the earliest stage of the disease. Microbial imbalance and low abundance of butyrate-producing bacteria, including Bifidobacterium adolescentis, may suggest benefits of microbial modification therapy. |
format | Online Article Text |
id | pubmed-6906406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69064062019-12-13 Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease Kowalska-Duplaga, Kinga Gosiewski, Tomasz Kapusta, Przemysław Sroka-Oleksiak, Agnieszka Wędrychowicz, Andrzej Pieczarkowski, Stanisław Ludwig-Słomczyńska, Agnieszka H. Wołkow, Paweł P. Fyderek, Krzysztof Sci Rep Article The aetiology of inflammatory bowel diseases (IBD) seems to be strongly connected to changes in the enteral microbiome. The dysbiosis pattern seen in Crohn’s disease (CD) differs among published studies depending on patients’ age, disease phenotype and microbiome research methods. The aims was to investigate microbiome in treatment-naive paediatric patients to get an insight into its structure at the early stage of the disease in comparison to healthy. Stool samples were obtained from controls and newly diagnosed patients prior to any intervention. Microbiota was analysed by 16SrRNAnext-generation-sequencing (NGS). Differences in the within-sample phylotype richness and evenness (alpha diversity) were detected between controls and patients. Statistically significant dissimilarities between samples were present for all used metrics. We also found a significant increase in the abundance of OTUs of the Enterococcus genus and reduction in, among others, Bifidobacterium (B. adolescentis), Roseburia (R.faecis), Faecalibacterium (F. prausnitzii), Gemmiger (G. formicilis), Ruminococcus (R. bromii) and Veillonellaceae (Dialister). Moreover, differences in alpha and beta diversities in respect to calprotectin and PCDAI were observed: patients with calprotectin <100 µg/g and with PCDAI below 10 points vs those with calprotectin >100 µg/g and mild (10–27.7 points), moderate (27.5–40 points) or severe (>40 points) CD disease activity had higher richness and diversity of gut microbiota. The results of our study highlight reduced diversity and dysbiosis at the earliest stage of the disease. Microbial imbalance and low abundance of butyrate-producing bacteria, including Bifidobacterium adolescentis, may suggest benefits of microbial modification therapy. Nature Publishing Group UK 2019-12-11 /pmc/articles/PMC6906406/ /pubmed/31827191 http://dx.doi.org/10.1038/s41598-019-55290-9 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Kowalska-Duplaga, Kinga Gosiewski, Tomasz Kapusta, Przemysław Sroka-Oleksiak, Agnieszka Wędrychowicz, Andrzej Pieczarkowski, Stanisław Ludwig-Słomczyńska, Agnieszka H. Wołkow, Paweł P. Fyderek, Krzysztof Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease |
title | Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease |
title_full | Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease |
title_fullStr | Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease |
title_full_unstemmed | Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease |
title_short | Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease |
title_sort | differences in the intestinal microbiome of healthy children and patients with newly diagnosed crohn’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906406/ https://www.ncbi.nlm.nih.gov/pubmed/31827191 http://dx.doi.org/10.1038/s41598-019-55290-9 |
work_keys_str_mv | AT kowalskaduplagakinga differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT gosiewskitomasz differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT kapustaprzemysław differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT srokaoleksiakagnieszka differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT wedrychowiczandrzej differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT pieczarkowskistanisław differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT ludwigsłomczynskaagnieszkah differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT wołkowpawełp differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease AT fyderekkrzysztof differencesintheintestinalmicrobiomeofhealthychildrenandpatientswithnewlydiagnosedcrohnsdisease |